Moderna (MRNA) SEC Filings: History & Chart

Moderna, Inc.(MRNA)

Biotechnology · Cambridge, MA

$145.55-3.32 (-2.23%)

Delayed quote: Sep 4, 2026, 4:00 PM EDT

About Moderna, Inc.

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Cambridge, MA

4,700 employees

www.modernatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stéphane Bancel

View full financials

Form	Filing Date	Accepted	Document
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
4	Sep 3, 2026	Sep 3, 2026	View filing
8-K	Sep 1, 2026	Sep 1, 2026	View filing
4	Aug 31, 2026	Aug 31, 2026	View filing
4	Aug 31, 2026	Aug 31, 2026	View filing
4	Aug 31, 2026	Aug 31, 2026	View filing
SC 13G	Aug 12, 2026	Aug 12, 2026	View filing
4	Aug 7, 2026	Aug 7, 2026	View filing
SC 13G/A	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Jul 31, 2026	Jul 31, 2026	View filing
8-K	Jul 31, 2026	Jul 31, 2026	View filing
SC 13G/A	Jul 24, 2026	Jul 24, 2026	View filing
4	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 10, 2026	Jul 10, 2026	View filing
3	Jul 10, 2026	Jul 10, 2026	View filing
8-K	Jul 8, 2026	Jul 8, 2026	View filing
4	Jul 7, 2026	Jul 7, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
3	Jun 30, 2026	Jun 30, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 29, 2026	May 29, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 18, 2026	May 18, 2026	View filing
8-K	May 11, 2026	May 11, 2026	View filing
4	May 8, 2026	May 8, 2026	View filing

SEC Filings

Recent Filings